Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8421 · 1 trial · 2 indications
Percentage of participants with incidence of DLTs.
Percentage of participants with incidence of AEs/SAEs.
Percentage of participants with clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.
Percentage of participants that have discontinued AZD8421 due to toxicity.
| Arm | Type | Description |
|---|---|---|
| Module 1 | EXPERIMENTAL | AZD8421 monotherapy |
| Module 2A | EXPERIMENTAL | AZD8421 with camizestrant and CDK4/6 inhibitor |
| Name | Type | Description |
|---|---|---|
| AZD8421 | DRUG | CDK2 inhibitor |
| Camizestrant | DRUG | SERD |
| Ribociclib | DRUG | CDK4/6 inhibitor |
| Palbociclib | DRUG | CDK4/6 inhibitor |
| Abemaciclib | DRUG | CDK4/6 inhibitor |
Inclusion Criteria: * Female participants only, aged 18 or above * Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical study is the best opti...
Top 20 of 92 competitors
AZD8421 is an investigational small molecule being studied for the treatment of ER+ HER2- advanced breast cancer. It is also being evaluated in high-grade serous ovarian cancer (HGSOC). The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AZD8421 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting a first-in-human study of the drug in patients with selected advanced or metastatic solid tumors.
AZD8421 is in Phase 1 clinical development. It is currently being evaluated in a first-in-human dose escalation and expansion study, which is actively recruiting participants. The drug is investigational and has not yet been approved for any use.
AZD8421 is being studied in clinical trial NCT06188520, a first-in-human dose escalation and expansion study. This Phase 1 trial is evaluating the safety and tolerability of AZD8421 alone or in combination in participants with ER+ HER2- advanced breast cancer and high-grade serous ovarian cancer. The trial is currently recruiting.
AZD8421 is a small molecule drug being developed for oncology indications. Its specific molecular target has not been disclosed in the available information. The drug is being studied for its potential to treat advanced solid tumors, including ER+ HER2- breast cancer and high-grade serous ovarian cancer.
No alternative names for AZD8421 have been disclosed. The drug is identified solely by its code name AZD8421 in clinical trial registrations and development programs. It is a distinct investigational compound being developed by AstraZeneca.